Presentation scheduled for tomorrow, Wednesday, June 3, 2020, at 10:00 AM ET NEW YORK , June 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat

The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib monotherapy NEW YORK , May 29, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the final results from the GENUINE Phase 3 study

NEW YORK , May 15, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that preclinical data for TG-1701, the Company’s highly selective, BTK inhibitor, has been selected for presentation at the upcoming 2020 American Association for Cancer Research (AACR) annual meeting,

NEW YORK , May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 8,500,000 shares of common stock at a

NEW YORK , May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it intends to offer and sell 6,000,000 shares of its common stock in

NEW YORK , May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 56 th American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually May 29 – June 1, 2020 and the 25 th European Hematology

NEW YORK , May 11, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2020 and recent company developments. Michael S. Weiss , the Company's Executive Chairman and Chief Executive Officer, stated, “The first few

NEW YORK , May 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Owen A. O’Connor, MD, PhD, has joined the Company as Chief Scientific Officer. Dr. O’Connor brings extensive scientific experience in developing drug candidates in oncology and hematology, and

$40 million of which came from longtime shareholder, RA Capital Management NEW YORK , May 06, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it has raised gross proceeds of approximately $60 million through its At-the-Market (ATM) facility, $40 million of which came

UNITY-CLL trial met the primary endpoint of improved progression-free survival (PFS) (p<.0001 and="" will="" be="" stopped="" early="" for="" superior="" efficacy="" observed="" at="" the="" interim="" analysis="" pfs="" benefit="" seen="" across="" both="" previously="" untreated="" relapsed="" patient="" populations="" regulatory="" submission="">